Increased risk of angioedema w/ ACE inhibitors. Aliskiren, & angiotensin II receptor blockers due to angiotensin II receptor blocking activity of Entresto. May increase the systemic exposure of OATP1B1 & OATP1B3 substrates eg, statins. Increase Cmax
& AUC of atorvastatin. Greater BP reduction w/ sildenafil. Increased serum K & serum creatinine w/ K-sparing diuretics (eg, triamterene, amiloride), mineralocorticoid antagonists (eg, spironolactone, eplerenone), K supplements or salt substitutes containing K. Increased risk of worsening of renal function w/ NSAIDs including COX-2 inhibitors. May increase serum conc & toxicity of lithium. May increase systemic exposure w/ rifampin, cyclosporine or ritonavir.